Navigation Links
From surgery to laboratory and back again
Date:2/11/2014

A University of York scientist's experience in seeing his partner in hospital recovering from a double lung transplant prompted him to design and synthesise new chemical agents that could revolutionise post-operative patient care.

Professor Dave Smith, of the University's Department of Chemistry, led an international team which developed the agents that bind and potentially remove the anti-coagulant heparin.

Professor Smith says: 'I was sitting at my husband Sam's bedside while he recovered from a double lung transplant when the idea first came to me. I spent a long time talking to surgeons about all the drugs they used, and some of the problems they caused, and as I sat there, looking at all the tubes, I realised that perhaps my research team could help."

One of the drugs used during major surgery is heparin which helps to prevent the blood from clotting. Once the patient is in recovery, however, the surgeons want clotting to resume to aid the healing process. To do this they use a 'heparin rescue agent', called protamine, to remove heparin from the patient's bloodstream. But in some cases, this can cause side effects such as patients going into anaphylactic shock. As a result, doctors must use protamine cautiously, which can lead to inefficient clotting.

"I realised that my research group had developed expertise which could lead to chemical agents to bind, and perhaps remove the heparin. These chemical agents can be carefully designed to minimise side effects and so improve patient care," Professor Smith says.

He designs small drug-like molecules, which assemble spontaneously into larger nanostructures in order to bind the heparin using multivalent (many-bonds) interactions. In the latest research, published in Chemical Science, Professor Smith and his team, which includes researchers from University of Liverpool, University of Trieste, and Freie Universitt Berlin demonstrate that this approach works in vitro in human plasma, reversing the effect of heparin and allowing clotting to begin.

Importantly, the system is biodegradable unless bound to heparin, with the molecules slowly breaking down, leading to nanostructure disassembly and inactivation. This means that, in principle, plenty of this compound could be used, because any excess will be less likely to cause side effects.

Professor Smith adds: "This could revolutionise the way in which surgeons reverse the effects of heparin once surgery is complete. I call this 'self-assembled multivalent' approach to medicine as 'SAMul' nanomedicine in honour of Sam who gave me the initial inspiration."

The next stages of the research will involve further optimisation of the agents to maximise their binding and further minimise their toxicity prior to in vivo testing and eventual clinical trials.


'/>"/>

Contact: David Garner
david.garner@york.ac.uk
44-019-043-22153
University of York
Source:Eurekalert

Related biology news :

1. Gastric banding patients should closely monitor nutrition following surgery
2. Using morphine after abdominal surgery may prolong pain, CU-Boulder researchers find
3. Findings announced from landmark study on safety of adolescent bariatric surgery
4. Parkinsons Surgery Research wins NSF Grant
5. Breast cancer surgery linked to swollen arm syndrome
6. Chris Christie, Governor of New Jersey, Slims Down after Having Lap Band Surgery
7. Research shows Vitamin D levels drop after pediatric heart surgery, increasing sickness
8. Improved material for laser welding of tissue in intestinal surgery
9. Study finds possible alternative to bariatric weight loss surgery
10. What you eat before surgery may affect your recovery
11. Physical activity linked to lower rates of depression in bariatric surgery patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/15/2016)... , December 15, 2016 Arvato ... an agreement with NuData Security, an award-winning international ... will enable clients to focus on good customer experience, balancing ... regulation. ... In order to provide a one-stop fraud prevention suite, Arvato ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 19, 2017 AquaBounty Technologies, Inc. (AIM: ABTU; ... in aquaculture and a majority-owned subsidiary of Intrexon Corporation ... completed the listing of its common shares on the ... Intrexon. "AquaBounty,s listing on NASDAQ represents an ... exposure to the U.S. markets as we advance plans ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
(Date:1/19/2017)... BD (Becton, Dickinson and Company) (NYSE: BDX ... host a live webcast of its Annual Meeting of Shareholders on ... The webcast can be accessed from the BD corporate website at ... 31, 2017. ... About BD BD is a global medical technology company that ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
Breaking Biology Technology: